Abstract

Objective: The objective of this study was to investigate the effects and possible mechanisms of action of ginseng on cerebral vasospasm and early brain injury (EBI) following hemorrhagic stroke. Materials and Methods: Sprague-Dawley (SD) rats (n = 48) were randomly divided into sham operation (sham group), subarachnoid hemorrhage (SAH) model (SAH group), normal saline (NS group), and Ginaton (Extract of Ginkgo Biloba Leaves Drops) intervention (gin group) groups. MCP-1 mRNA and tumor necrosis factor levels were detected using reverse transcription–polymerase chain reaction. The relative expression of mRNA was detected by Western blotting. Results: (1) Compared with the sham group, the SAH, NS, and gin groups had different degrees of neurological dysfunction. Compared with the SAH and NS groups, the neurological deficits in the gin group were significantly improved (P < 0.05). (2) Compared with the sham group, the relative expression levels of MCP-1 mRNA in the SAH, NS, and gin groups were 5.1 ± 0.9, 3.4 ± 0.6, and 2.5 ± 0.4, respectively; the relative expression levels of mRNA were 13.3 ± 2.4, 11.2 ± 1.8, and 3.8 ± 0.6, respectively. (3) The apoptosis rates of brain tissue in the sham, SAH, NS, and gin groups were 4.8 ± 0.7, 54.2 ± 10.3, 50.1 ± 7.4, and 28.4 ± 4.5, respectively. (4) Western blot showed that the relative expression levels of toll-like receptor-4 (TLR-4) protein in the sham, SAH, NS, and gin groups were 0.29 ± 0.03, 0.87 ± 0.15, 0.65 ± 0.13, and 0.41 ± 0.17, respectively; the relative expression levels of B protein were 0.21 ± 0.04, 0.96 ± 0.14, 0.73 ± 0.18, and 0.30 ± 0.05, respectively. Gin treatment could inhibit TLR-4 and nuclear factor-κB (NF-κB) protein expression. Conclusions: Dona tablets may inhibit activation of the NF-κB signaling pathway, and SAH-induced inflammatory response, so as to reduce cerebral vasospasm and EBI.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call